Skip to main content

news

 

Shardul Amarchand Mangaldas & Co has advised Netherlands-headquartered speciality ingredient solutions provider Barentz International on its acquisition of India-based Anshul Life Sciences, which was represented by AZB & Partners.

Financial terms of the deal were not disclosed, but media sources put it at 170 million euros ($188 million).

The acquisition establishes a life sciences distribution platform for Barentz in India, with expected strategic growth opportunities across the Asia Pacific region. Anshul Life Sciences is a speciality chemical distributor focused on the regulated pharmaceutical, food and nutraceutical, and personal care markets.

The SAM team was led by partners Roopal Kulsrestha, Neelam Pathak, and Meghna Nachappa, and included associates Aparna R, Sandra Anil Varkey, Pranav Bajaj, and Sidharth Chamarthy.

The AZB team included senior partner Vaidhyanadhan Iyer and partner Sneha Nagvekar, along with associates Deepti Narayanan, Priyasha Goyal, Jay Singhee, and Meghna Somani.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

CAM, Trilegal, Khaitan, IndusLaw act on HUL’s $350 mln Minimalist deal

by Nimitt Dixit |

In the first big M&A deal in India this year, leading firm Cyril Amarchand Mangaldas has guided FMCG major Hindustan Unilever (HUL) on its acquisition of 90.5 percent stake in Jaipur-based skincare startup Minimalist for close to $350 million (29.5 billion rupees).

Deals

7 international, Indian firms act on Kedaara Capital’s $350 mln U.S. bet

by Nimitt Dixit |

Akin Gump Strauss Hauer & Feld, Quillon Partners, and Kelley Drye & Warren have advised Indian private equity firm Kedaara Capital on its maiden bet in the data analytics and AI solutions market, committing $350 million strategic investment to San Jose, California-based Impetus Technologies.

Deals

Saraf, TT&A facilitate Fortis’ $207 mln buyout of PE investors in Agilus Diagnostics

by Nimitt Dixit |

Saraf and Partners has acted for Fortis Healthcare in relation to the $207 million acquisition of a 31.5 percent equity stake in its subsidiary, Agilus Diagnostics, from three private equity investors.